Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
Part of paid clinical trials in Mesa, Arizona.
- Sponsor
- Kyowa Kirin Co., Ltd.
- Study ID
- NCT06116916
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Diabetic Macular Edema (DME)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- KHK4951 — DRUGKHK4951 eye drop for 36 weeks until end of the trial
- Aflibercept Injection — DRUGIntravitreal injection (IVT) of aflibercept will be given as specified in the protocol
Study Details
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
Key Dates
- Start date
- Jan 9, 2024
- Status verified
- Oct 2025
- Primary completion
- Aug 31, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 150 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm AKHK4951 High dose
- Experimental: Arm BKHK4951 Middle dose
- Experimental: Arm CKHK4951 Low dose
Primary Outcome Measure
Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baseline [ Time Frame: For 36 weeks until the end of the trial ]
Locations (40)
Find similar trials in Mesa, AZ
Related Studies
- High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous VitrectomyPHASE4 · Recruiting · Retina Consultants of Orange County · Fullerton, California
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · Recruiting · EyePoint Pharmaceuticals, Inc. · Gilbert, Arizona
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · Recruiting · EyePoint Pharmaceuticals, Inc. · Bakersfield, California
- Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsPHASE4 · Enrolling By Invitation · Harrow Inc · Tyler, Texas